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The hybridisation of an Affymetrix HG_U95Av2 oligonucleotide array with RNAs extracted from six human thyroid carcinoma cell
lines and a normal human thyroid primary cell culture led us to the identification of the UbcH10 gene that was upregulated by 150-
fold in all of the carcinoma cell lines in comparison to the primary culture cells of human normal thyroid origin. Immunohistochemical
studies performed on paraffin-embedded tissue sections showed abundant UbcH10 levels in thyroid anaplastic carcinoma samples,
whereas no detectable UbcH10 expression was observed in normal thyroid tissues, in adenomas and goiters. Papillary and follicular
carcinomas were only weakly positive. These results were further confirmed by RT–PCR and Western blot analyses. The block of
UbcH10 protein synthesis induced by RNA interference significantly reduced the growth rate of thyroid carcinoma cell lines. Taken
together, these results would indicate that UbcH10 overexpression is involved in thyroid cell proliferation, and may represent a
marker of thyroid anaplastic carcinomas.
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Tumours are the result of the accumulation of different modifica-
tions in critical genes involved in the control of cell proliferation.
In a large number of carcinomas with worst prognosis, lesions are
not diagnosed until the disease is at an advanced stage. Although
various therapeutic approaches are followed in clinical practice,
most of them are not life saving. Hence, the discovery of ways to
diagnose cancer at an early stage and to establish more effective
therapies is a critical and urgent issue. To achieve this goal,
identification and characterisation of key molecules that partici-
pate in carcinogenesis are essential steps. Thyroid neoplasms
represent a good model for studying the events involved in
epithelial cell multistep carcinogenesis, because they comprise a
broad spectrum of lesions with different degrees of malignancy
from benign adenomas, which are not invasive and very well
differentiated, to the undifferentiated anaplastic thyroid carcino-
mas, which are very aggressive and always fatal; papillary and
follicular carcinomas, the most common forms of thyroid cancer,
represent intermediate forms of neoplasia being differentiated and
having a good prognosis (Hedinger et al, 1989; Wynford-Thomas,
1997).
The involvement of several oncogenes has been demonstrated in
papillary thyroid carcinomas. Activation of the RET/PTC onco-
gene, caused by rearrangements of the RET protooncogene, is
detectable in about 30% of the cases (Grieco et al, 1990; Tallini
et al, 1998). Mutations of the B-RAF gene have been demonstrated
in almost 40% of papillary carcinomas (Fukushima et al, 2003).
TRK gene rearrangements (Pierotti et al, 1995) and MET gene
overexpression are often found in papillary carcinomas (Di Renzo
et al, 1992). RAS gene mutations (Suarez et al, 1990) and PAX8-
PPAR-g rearrangements (Kroll et al, 2000) are frequently detected
in tumours of the follicular type. Impairment of the p53 tumour
suppressor gene function represents a typical feature of the
anaplastic carcinomas (Ito et al, 1992; Dobashi et al, 1993; Donghi
et al, 1993; Fagin et al, 1993; Matias-Guiu et al, 1994). Even though
critical molecular mechanisms of thyroid carcinogenesis have been
clarified, other molecular steps of neoplastic progression need to
be investigated.
Therefore, to identify the genes regulated in the process of
thyroid carcinogenesis, we analysed a microarray with RNAs
extracted from normal human thyroid primary cell culture
(NTPC), and six human thyroid carcinoma cell lines of different
histotype (one from a follicular carcinoma, three derived from
papillary carcinomas and two from anaplastic carcinomas). Our
attention was focused on the UbcH10 gene that was upregulated
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sabout 150-fold in all of the cell lines tested by the cDNA
microarray. The UbcH10 gene belongs to the E2 gene family and
codes for a protein of 19.6kDa that is involved in the ubiquitin-
dependent proteolysis. In this pathway, ubiquitin-conjugating
enzyme (E2), together with ubiquitin ligase (E3), transfers
ubiquitin to specific substrate proteins (Hershko and Ciechanover,
1998; Joazeiro and Weissman, 2000).
The expression level of UbcH10 was extremely low in the normal
thyroid primary culture cells, but strong in all the cancerous cell
lines. Immunohistochemical and RT–PCR analyses on a large
panel of thyroid neoplasms of different histotypes revealed an
increased UbcH10 expression in anaplastic thyroid carcinomas,
whereas follicular and papillary carcinomas were just weakly
positive. The block of UbcH10 protein synthesis by RNA
interference inhibited the growth of two thyroid carcinoma cell
lines.
MATERIALS AND METHODS
Cell culture and transfections
The human thyroid carcinoma cell lines used in this study are:
TPC-1 (Tanaka et al, 1987), WRO (Estour et al, 1989), NPA and
ARO (Pang et al, 1989), FRO (Fagin et al, 1993), NIM 1 (Zeki et al,
1993), B-CPAP (Fabien et al, 1994), FB-1 (Fiore et al, 1997), FB-2
(Basolo et al, 2002), Kat-4 and Kat-18 (Ain et al, 1997). They were
grown in DMEM (Gibco Laboratories, Carlsbad, CA, USA)
containing 10% fetal calf serum (Gibco Laboratories), glutamine
(Gibco Laboratories) and ampicillin/streptomycin (Gibco Labora-
tories) in a 5% CO2 atmosphere. Normal human thyroid primary
culture cells have been established and grown as already described
(Curcio et al, 1994). PC Cl 3 cell line derived from Fischer rat
thyroid (Fusco et al, 1987) was cultured in modified F12 medium
supplemented with 5% calf serum (Gibco Laboratories) and six
growth factors (thyrotropic hormone, hydrocortisone, insulin,
transferrin, somatostatin and glycyl-histidyl-lysine; Sigma, St
Louis, MO, USA). Thyroid cells were transfected using Lipofecta-
mine reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. The transfected cells were selected in
a medium containing geneticin (G418) (Life Technologies, Italy).
For each transfection, several G418-resistant clones and the mass
cell population were isolated and expanded for further analysis.
Human thyroid tissue samples
Neoplastic human thyroid tissues and normal adjacent tissue or
the controlateral normal thyroid lobe were obtained from surgical
specimens and immediately frozen in liquid nitrogen. Thyroid
tumours were collected at the Service d’Anatomo-Pathologie,
Centre Hospitalier Lyon Sud, Pierre Be ´nite, France. The tumour
samples were stored frozen until RNA or protein extractions were
performed.
RNA isolation
Total RNA was extracted from tissues and cell cultures using the
RNAeasy mini kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions. The integrity of the RNA was assessed
by denaturing agarose gel electrophoresis.
Reverse transcriptase–PCR analysis
In total, 5mg of total RNA from each sample, digested with DNAseI
(Invitrogen), were reverse transcribed using random hexanucleo-
tides and MuLV reverse transcriptase (Applied Biosystems, Foster
City, CA, USA). PCR was carried out on cDNA using the GeneAmp
PCR System 9600 (Applied Biosystems). RNA PCR Core Kit
(Applied Biosystems) was used to perform RT–PCR reactions.
For the UbcH10 gene, after a first denaturing step (941Cf o r3m i n ) ,
PCR amplification was performed for 25 cycles (941C for 30s, 571C
for 30s, 721C for 30s). The sequences of forward and reverse
primers, amplifying a fragment of 115bp in the UbcH10 cDNA,
were: forward 50-GCCCGTAAAGGAGCTGAG-30 and reverse 50-
GGGAAGGCAGAAATCCCT-30. The human b-actin gene primers,
amplifying a 109bp cDNA fragment, were used as control;
amplification was performed for 25 cycles (941C for 30s, 551Cf o r
30s, 721C for 30s). b-Actin-forward, 50-TCGTGCGTGACATTAAG
GAG-30; b-actin-reverse, 50-GTCAGGCAGCTCGTAGCTCT-30.T o
ensure that RNA samples were not contaminated with DNA,
negative controls were obtained by performing the PCR on samples
that were not reverse-transcribed, but otherwise identically
processed. The PCR products were separated on a 2% agarose gel,
stained with ethidium bromide and scanned using a Typhoon 9200
scanner. Quantitative PCR was performed in triplicate using iCycler
(Bio-Rad, Hercules, CA, USA) with SYBR
s Green PCR Master Mix
(Applied Biosystems) as follows: 951C 10min and 40 cycles (951C
15s and 601C 1min). Fold mRNA overexpression was calculated
according to the formula 2
(Rt Et)/2
(Rn En) as described previously
(El-Rifai et al, 2001), where Rt is the threshold cycle number for the
reference gene in the tumour, Et for the experimental gene in the
tumor, Rn for the reference gene in the normal sample and En for
the experimental gene in the normal sample.
Protein extraction, Western blotting and antibodies
Cells were washed once in cold PBS and lysed in a lysis buffer
containing 50mM HEPES, 150mM NaCl, 1mM EDTA, 1mM EGTA,
10% glycerol, 1% Triton-X-100, 1mM phenylmethylsulphonyl
fluoride, 1mg aprotinin, 0.5mM sodium orthovanadate, 20mM
sodium pyrophosphate. The lysates were clarified by centrifuga-
tion at 14000r.p.m. 10min. Protein concentrations were esti-
mated by a Bio-Rad assay (Bio-Rad), and boiled in Laemmli buffer
(Tris-HCl pH 6.8, 0.125 M, SDS 4%, glycerol 20%, 2-mercaptoetha-
nol 10%, bromophenol blue 0.002%) for 5min before electrophor-
esis. Proteins were subjected to SDS–PAGE (15% polyacrylamide)
under reducing condition. After electrophoresis, proteins were
transferred to nitrocellulose membranes (Immobilon-P Millipore
Corp., Bedford, MA, USA); complete transfer was assessed using
prestained protein standards (Bio-Rad). After blocking with TBS-
BSA (25mM Tris, pH 7.4, 200mM NaCl, 5% bovine serum
albumin), the membrane was incubated with the primary antibody
against UbcH10 (Boston Biochem Inc., Cambridge, MA, USA) for
60min (at room temperature). Primary antibody against c-Fos
protein (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was
used to confirm the specificity of siRNAs against UbcH10 protein.
To ascertain that equal amounts of protein were loaded, the
Western blots were incubated with antibodies against the g-tubulin
protein (Sigma). Membranes were then incubated with the
horseradish peroxidase-conjugated secondary antibody (1:3000)
for 60min (at room temperature) and the reaction was detected
with a Western blotting detection system (ECL; Amersham
Biosciences, UK).
Immunohistochemistry: tissue samples
UbcH10 protein cellular distribution was assessed by immunohis-
tochemical analysis and compared to that of the standard cell
proliferation marker Ki-67/MIB1. A series of surgical specimens
from patients with thyroid diseases comprised of Hashimoto’s
thyroiditis-HT (six cases), nodular goiter (12 cases), follicular
carcinoma (13 cases), papillary carcinoma (33 cases), poorly
differentiated carcinoma (five cases) and anaplastic carcinoma (15
cases) was chosen to represent a wide range of thyroid pathology.
As control, 10 areas of normal thyroid parenchyma were selected
from the lobe controlateral to the tumour in surgical specimens of
papillary carcinoma.
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sImmunostaining: technique, evaluation and statistical
analysis
Xylene dewaxed and alcohol-rehydrated paraffin sections were
placed in Coplin jars filled with a 0.01 M tri-sodium citrate solution,
and heated for 3min in a conventional pressure cooker (Troncone
et al, 2003). After heating, slides were thoroughly rinsed in cool
running water for 5min. They were then washed in Tris-Buffered
Saline (TBS) pH 7.4 before incubating overnight with the specific
antibody, diluted as follows: rabbit polyclonal a-UbcH10 (Boston
Biochem) 1:1000; a-MIB-1 (Novocastra, Newcastle upon Tyne,
UK) 1:50. After incubation with the primary antibody, tissue
sections were stained with biotinylated anti-rabbit or anti-mouse
immunoglobulins, followed by peroxidase-labelled streptavidine
(Dako, Carpinteria, CA, USA); the signal was developed by using
diaminobenzidine (DAB) chromogen as substrate. Incubations
both omitting the specific antibody, and including unrelated
antibodies, were used as negative controls.
Individual cells were scored for expression of UbcH10 and Ki-67
in similar areas of adjacent sections by quantitative analysis
performed with a computerised analyser system (Ibas 2000,
Kontron, Zeiss), as already described (Troncone et al, 2003). In
each case, the distribution of these proteins was evaluated in at
least 500 epithelial follicular cells and expressed as a percentage of
the total cell population. The statistical analysis was performed
using SPSS
‘Ver. 9.0.1 for Windows’. Data are expressed as median
value and range. The nonparametric Mann–Whitney U-test was
used to compare differences in labelling indexes for UbcH10 and
Ki-67 in thyroid carcinomas. The Spearman rank order correlation
was used to verify the association between UbcH10 and Ki-67. A
P-value less than 0.05 was considered statistically significant.
RNA interference
For small interfering RNA (siRNA) experiments, the following
double-strand RNA oligo specific for UbcH10 coding region was
used: 50-AACCTGCAAGAAACCTACTCA-30 as previously de-
scribed (Wagner et al, 2004). As negative control, we used a
corresponding scrambled sequence as follows: 50-AACTAACAC
TAGCTCAAGACC-30. All of the siRNA duplexes were purchased
from Qiagen and were transfected using Oligofectamine (Invitro-
gen) according to the manufacturer’s recommendations. Small
interfering RNAs were used at a final concentration of 100nM and
12 10
5 cellswell
 1 were plated in a six-well format plates.
Proteins were extracted 48h after siRNA treatment and the levels
of the UbcH10 protein were evaluated by Western blot.
Assay of the transformed state
Tumorigenicity of the cell lines was tested by injecting 2 10
6 cells
subcutaneously into athymic mice. Soft agar colony assay was
performed as previously described (Macpherson and Montagnier,
1964).
RESULTS
Expression of UbcH10 gene in normal human thyroid cells
and thyroid carcinoma cell lines
To search for candidate genes involved in the neoplastic
transformation of thyroid gland, RNAs extracted from normal
human thyroid primary cells and six human thyroid carcinoma
cell lines of different origin (WRO cell line from a follicular
carcinoma, TPC-1 and FB-2 cell lines, both deriving from papillary
thyroid cancers, NPA cell line, which derives from a poorly
differentiated papillary carcinoma, ARO and FRO cell lines
originating from anaplastic carcinomas) were hybridised to
U95Av2 Affymetrix oligonucleotide arrays (data not shown). We
concentrated our attention on the UbcH10 gene that was
upregulated about 150-fold in all of the cell lines tested by the
cDNA microarray. This result was confirmed by RT–PCR in a
larger panel of thyroid carcinoma cell lines using as control normal
thyroid primary culture (Figure 1A). Western blot analysis of
UbcH10 expression, shown in Figure 1B, confirmed the RT–PCR
data. In fact, the UbcH10 protein was abundantly expressed in all
of the carcinoma cell lines, whereas it was barely detectable in
normal thyroid cells.
Analysis of UbcH10 expression in normal and neoplastic
thyroid tissues by immunohistochemistry, Western blot
and RT–PCR
In order to evaluate whether the overexpression of UbcH10 is a
feature of the thyroid tumours and not only of cultured thyroid
carcinoma cell lines, we performed immunohistochemical analysis
using a commercial antibody against UbcH10 protein. This
methodology allows a rapid and sensitive screening of thyroid
pathological tissues and is amenable to regular use as a routine
diagnostic test. To find the best experimental conditions, ARO cell
line and tumours, induced by injecting the ARO cell line into
athymic mice, were used as positive controls (Cerutti et al, 1996).
No staining was observed with normal human thyroid primary cell
culture, whereas a positive staining was obtained with ARO cell
line and ARO-induced tumours (data not shown). We found that
normal thyroid, nodular goiter and Hashimoto’s thyroiditis (HT)
were almost always completely negative for UbcH10 expression.
Only occasionally, single UbcH10-labelled thyroid epithelial cells
showing mitotic figures could be observed by meticulous scrutiny
(Figure 2A). In HT, there was a sharp contrast between the
negative epithelial oxyphilic cells and the positive lymphoid
germinal centers (Figure 2B). While a weak staining is detectable
in follicular adenomas (Figure 2C), higher levels of UbcH10 were
recorded in papillary (median value 2.2% of positive cells; range
0.9–4.1%), follicular (median value 2.8% of positive cells; range 1–
6.1%) and poorly differentiated (median value 10.4% of positive
cells; range 8–14.9%) carcinomas, signal being always easily
detectable in the nuclei of scattered neoplastic cells (Figure 2D, E
and F). UbcH10 staining pattern was somewhat different in
NTPC
WRO
N-PAP
TPC-1
BC-PAP
NIM
FRO
ARO
KAT-4
KAT-18
FB-1
FB-2
NTPC
WRO
N-PAP
TPC-1
BC-PAP
NIM
FRO
ARO
KAT-4
KAT-18
FB-1
FB-2
UbcH10
UbcH10
-Actin
-Tubulin
A
B
Figure 1 UbcH10 expression in human thyroid carcinoma cell lines. (A)
UbcH10 gene expression analysis by RT–PCR in human thyroid carcinoma
cell lines vs the normal human thyroid primary culture cells (NTPC). b-
Actin gene expression was evaluated as control to normalise the amount of
the used RNAs. (B) UbcH10 protein expression analysis by Western Blot
in human thyroid carcinoma cell lines. Blot against g-tubulin has been
performed as control for equal protein loading.
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sanaplastic carcinomas, the percentage (median value 45.8% of
positive cells; range 38.8–56.2%) of stained cells being large and
the intensity of the neoplastic cells being strong (Figure 2G and H).
No staining was observed when the same anaplastic carcinoma
samples were stained with antibodies preincubated with UbcH10
recombinant protein (Figure 2I) or in the absence of the primary
antibodies (data not shown). Therefore, as a general rule, UbcH10
expression is negligible in non-neoplastic thyroid, noticeable in
well-differentiated carcinomas and conspicuous in less-differen-
tiated tumours (Figure 3A).
To determine the relationship between UbcH10 expression and
tissue proliferation, we correlated its expression in carcinomas
with the proliferation rate of thyrocytes, as measured by Ki-67
staining; this latter showed the same tissue distribution of UbcH10,
which was evident when adjacent (mirror) sections were stained.
By using the Spearman rank order correlation, we determined that
the association between UbcH10 and Ki-67 expression in thyroid
cancer was statistically significant. In fact, the value of the
Spearman R was 0.4 (Po0.001) (Figure 3B).
Western blot analysis, performed on 30 surgically removed
thyroid tumours, confirmed the immunohistochemical data. A
representative Western blot is shown in Figure 4A. A strong band
of 19.6kDa corresponding to the UbcH10 protein was detected in
anaplastic thyroid carcinomas and a weak one in poorly
differentiated carcinomas, but not in papillary carcinomas and
normal thyroids. These data strongly indicate that the expression
of UbcH10 is more abundant in thyroid carcinomas characterised
by a highly malignant and aggressive phenotype. Equal amounts of
total proteins were used for each sample as demonstrated by the
same gel analysed with an antibody against g-tubulin.
UbcH10 expression was also evaluated by RT–PCR analysis on a
panel of matched tumour/normal tissues. This analysis confirmed
the protein data. In fact, as shown in Figure 4B, an amplified band
of 115bp was clearly detected in the anaplastic and poorly
differentiated carcinoma samples, but not in the papillary ones and
in all the corresponding normal thyroid tissues. Finally, quanti-
tative RT–PCR analysis confirmed a great increase of UbcH10
expression in thyroid anaplastic samples, whereas a light increase
was observed in papillary carcinoma samples (Figure 4C).
UbcH10 expression in experimental models of thyroid
carcinogenesis
Thyroid neoplasias developing in transgenic animal lines expres-
sing TRK (Tg-TRK) (Russell et al, 2000), RET/PTC3 (Tg-RET/
PTC3) (Powell et al, 1998) and large T SV40 (Tg-SV40) (Ledent
et al, 1991) oncogenes under the transcriptional control of the
thyroglobulin promoter have been analysed for UbcH10 expres-
sion by Western blot analysis. Transgenic mice carrying TRK and
RET/PTC3 oncogenes develop thyroid papillary carcinomas
(Powell et al, 1998; Russell et al, 2000); thyroid anaplastic
carcinomas were, conversely, obtained in the Tg-SV40 mice
ABC
F
I H
E D
G
Figure 2 UbcH10 staining pattern in normal, inflammatory and neoplastic thyroid tissues. Follicular epithelial cells of normal thyroid (A) and oxyphilic cells
of Hashimoto’s thyroiditis (HT) (B) do not stain for UbcH10, with occasional mitotic figures (A, arrow) and lymphoid centroblasts of HT (B, arrow)
providing the appropriate internal positive control. In neoplastic thyroid, UbcH10 staining pattern is strongly related to tumour grade, being weak in follicular
adenoma (C), slightly more evident in well-differentiated papillary (D) and follicular (E) carcinomas, whereas stronger in poorly differentiated (F) and in
anaplastic (G) carcinomas. In the latter, most of neoplastic cells show a very intense labelling, with intense nuclear staining (H), whereas signal disappeared by
antigen incubation (I).
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s(Ledent et al, 1991). As shown in Figure 5, elevated UbcH10
protein levels were observed in the thyroid anaplastic carcinomas
derived from large TSV40 transgenic mice. Conversely, UbcH10
protein was absent in normal mouse thyroid tissue and in the
papillary carcinomas originating from TRK and RET/PTC3 mice.
Therefore, the analysis of the experimental models of thyroid
carcinogenesis seems to confirm that the UbcH10 overexpression
is essentially restricted to the undifferentiated histotype.
Suppression of the UbcH10 synthesis inhibits thyroid
carcinoma cell growth
We asked whether UbcH10 overexpression had a role in the
process of thyroid carcinogenesis by evaluating the growth rate of
two thyroid carcinoma cell lines, in which UbcH10 protein was
suppressed by RNA interference. The NPA and TPC-1 cell lines
were treated with siRNA duplexes targeting to the UbcH10 mRNA.
After transfection, we observed an efficient knockdown of the
UbcH10 protein levels at 48h after treatment (Figure 6A). The
analysis of cell growth of these cell lines in the presence or absence
of the UbcH10 siRNA duplexes revealed that the block of the
UbcH10 protein synthesis significantly inhibits thyroid carcinoma
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Figure 3 Statistical analysis of the immunohistochemical data. (A)
Protein expression of UbcH10 (% positive cells) progressively increases in
the several diagnostic categories from thyroid goiter to the thyroid
anaplastic carcinomas. The analysis has been carried out using the Kruskal–
Wallis test. HT, Hashimoto’s thyroiditis; PTC, papillary thyroid carcinoma;
FTC, follicular thyroid carcinoma; PDC, poorly differentiated thyroid
carcinoma; ATC, anaplastic thyroid carcinoma. (B) Protein expression of
UbcH10 (% positive cells) is correlated to that of Ki-67 (% positive cells) in
the several diagnostic categories. The analysis has been carried out
calculating the Spearman rank correlation coefficient.
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Figure 4 UbcH10 expression in human thyroid fresh tumour samples.
(A) Western blot analysis of UbcH10 protein expression in a panel of
thyroid neoplasias. The level of g-tubulin has been used as loading control.
NT, normal thyroid tissue; PTC1 and PTC2, papillary thyroid carcinomas
from two different patients; PDC1, poorly differentiated carcinoma; ATC1,
anaplastic thyroid carcinoma. (B) RT–PCR analysis of UbcH10 expression
in human thyroid tumour samples vs their normal thyroid counterparts. b-
Actin expression shows the same amount of RNAs used. NT, normal
thyroid tissue; PTC1 and PTC2, papillary thyroid carcinomas from two
different patients; PDC1, poorly differentiated carcinoma; ATC1 and ATC2,
anaplastic thyroid carcinomas from two different patients. (C) Quantitative
RT–PCR analysis was performed on human thyroid tumour samples of
different histotype. The Fold Change values indicate the relative change in
the expression levels between tumour samples and normal samples,
assuming that the value of each normal sample is equal to 1.
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Figure 5 UbcH10 expression in experimental mouse thyroid tumours.
Western blot analysis of experimental thyroid carcinomas developed in
transgenic mice expressing TRK, RET-PTC-3 and large T SV40 oncogenes.
ARO cell line was used as positive control. g-Tubulin shows the same
amount of protein level.
UbcH10 in thyroid carcinomas
P Pallante et al
468
British Journal of Cancer (2005) 93(4), 464–471 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
scell growth. In fact, as shown in Figure 6B, a significant reduction
in cell growth rate was observed in NPA and TPC-1 cell lines
treated with UbcH10 siRNA in comparison to the untreated cells or
those treated with the control scrambled siRNA.
These results indicate a role of UbcH10 in neoplastic thyroid cell
proliferation.
UbcH10 overexpression is not sufficient to transform rat
thyroid cells
To further characterise the role of UbcH10 in thyroid carcinogen-
esis, we transfected normal rat thyroid cells with an expression
vector carrying the UbcH10 gene under the transcriptional control
of the cytomegalovirus promoter. The selected clones were shown
to express high UbcH10 protein levels (data not shown). We
evaluated the growth rate of the UbcH10-transfected PC Cl 3 cells
and the same cells transfected with a backbone vector: no
differences were observed. Equally, the neoplastic phenotype of
the UbcH10-transfected PC Cl 3 cells was evaluated by a soft agar
colony assay and by injection into athymic mice. As reported in
Table 1, the PC Cl 3 cells transfected with the UbcH10 expression
vector were not able to give rise to colonies in soft agar and induce
tumours in athymic mice. As a positive control, we used the PC Cl
3 cells transformed with the Myeloproliferative sarcoma virus (PC
MPSV): these cells have a very highly malignant phenotype (Fusco
et al, 1987).
These results indicate that UbcH10 overexpression is not able to
transform rat thyroid cells in vitro.
DISCUSSION
Thyroid neoplasms represent an excellent model for studying the
process of cell transformation since they include a broad spectrum
of histotypes showing different degree of malignancy (Hedinger
et al, 1989; Wynford-Thomas, 1997). From the Affymetrix
microarray analysis, we found the UbcH10 gene that appeared
greatly increased in all of the thyroid carcinoma cell lines. UbcH10
was previously identified as a human homologue of the cyclin-
selective E2 (E2-c), which is required for the destruction of mitotic
cyclins by the ubiquitination pathway. The UbcH10 gene belongs
to the E2 gene family and codes for a protein of 19.6kDa that is
involved in the ubiquitin-dependent proteolysis. In this system,
three distinct enzymes cooperate to process target proteins for
degradation. More precisely, the ubiquitin-conjugating enzyme
(E2) transfers activated ubiquitin by ubiquitin-activating enzyme
(E1) to a lysine residue of the target proteins in cooperation with
the ubiquitin-ligase (E3). Polyubiquitinated proteins are then
recognised by the 26S proteasome and rapidly degraded (Hershko
and Ciechanover, 1998; Joazeiro and Weissman, 2000).
In our study, we have evaluated the expression of UbcH10 in
human thyroid neoplasias and in mouse experimental tumours. No
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Figure 6 The block of UbcH10 protein synthesis by RNA interference
inhibits the proliferation of thyroid carcinoma cells. (A) Inhibition of
UbcH10 protein expression by RNAi in NPA and TPC-1 cell lines
evaluated by Western blot analysis. At 48h after siRNA transfection, total
cell lysates were prepared and normalised for protein concentration. The
expression of g-tubulin was used to control equal protein loading (30mg).
In this figure, we also show the expression of a fast turning-over gene like c-
Fos to confirm the specific effect of siRNAs against UbcH10. (B) Growth
curves of NPA and TPC-1 cell lines after siUbcH10 treatment. NPA and
TPC-1 cells were transfected with siUbcH10 duplexes (siUbcH10) and the
relative number of viable cells was determined by MTT assay. Cells
transfected with a scrambled duplex (siScrambled) and untransfected cells
(Untransfected) were used as negative controls. Absorbance was read at
570nm and the data are the mean of triplicates.
Table 1 Analysis of the neoplastic phenotype of the UbcH10-
transfected rat thyroid cell lines
Cell line
Doubling time
(h)
Colony-
forming
a
efficiency (%)
Tumour
b
incidence
PC CL 3 24 0 0/4
PC UbcH10 CL1 24 0 0/4
PC UbcH10 CL2 23 0 0/4
PC MPSV 18 70 4/4
aColony-forming efficiency was calculated by the formula (number of colonies
formed/number of plated cells) 100.
bTumorigenicity was assayed by injecting
2 10
6 cells into athymic mice (4–6 weeks old).
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goiters and adenomas, whereas a great induction of UbcH10
expression was observed in anaplastic human thyroid carcinomas
and in experimental undifferentiated thyroid tumours. Just a weak
expression of UbcH10 was observed in follicular and papillary
human thyroid carcinomas. Therefore, these data strongly indicate
that UbcH10 overexpression could be associated with the thyroid
tumour progression since there is a good correlation with the late
stage of thyroid neoplastic transformation. The low UbcH10 levels
detected in the differentiated thyroid malignancies would appear
in contrast with the data showing an abundant UbcH10 expression
in the cell lines deriving from differentiated carcinomas. We retain
this discrepancy only apparent since thyroid carcinoma cell lines,
even deriving from differentiated tumours, cannot be completely
compared to surgically removed tumours. In fact, these cell lines
harbour p53 mutations that are rare in thyroid differentiated
neoplasias (Tanaka et al, 1987; Estour et al, 1989; Pang et al, 1989;
Ito et al, 1992; Dobashi et al, 1993; Donghi et al, 1993; Fagin et al,
1993; Zeki et al, 1993; Fabien et al, 1994; Matias-Guiu et al, 1994;
Ain et al, 1997; Fiore et al, 1997; Basolo et al, 2002) and they have a
high proliferation rate. However, this consideration does not
exclude the validity of the use of the thyroid carcinoma cell lines as
experimental model to draw new information that, however, need
to be subsequently validated on fresh tumours.
Our results also indicate a correlation between UbcH10 over-
expression and the proliferation status since there is a good
association with the proliferation marker Ki-67/MIB1.
An aim of our work was to evaluate the possible causal role of
UbcH10 overexpression in thyroid carcinogenesis. Indeed, the
block of protein synthesis significantly inhibited the growth of
several thyroid carcinoma cell lines, suggesting an important role
of UbcH10 in thyroid cell proliferation, and then in the
progression step of thyroid carcinogenesis.
Therefore, even though the mechanisms by which UbcH10
overproduction contributes to the neoplastic phenotype remains
unclear, we can assume that it leads to a deregulation of cell
growth. These results are quite consistent with previous published
data showing that UbcH10 was expressed at high levels in primary
tumours derived from the lung, stomach, uterus, and bladder as
compared with their corresponding normal tissues, suggesting that
UbcH10 is involved in tumorigenesis or cancer progression
(Okamoto et al, 2003; Wagner et al, 2004). It has also been shown
that UbcH10 is upregulated in NIH3T3 cell line transformed by
EWS/FLI1, but not in untransformed NIH3T3 cell clone expressing
EWS/FLI1 (Arvand et al, 1998). Moreover, it has been shown that
UbcH10 is required for override metaphase, likely degrading
growth suppressor, and for destruction of mitotic cyclins,
indicating a role of UbcH10 in cell cycle progression (Arvand
et al, 1998).
However, overexpression of UbcH10 in normal rat thyroid cells
did not affect cell growth neither induced a malignant phenotype,
indicating that UbcH10 overexpression is not sufficient for
malignant thyroid cell transformation. This result might appear
in contrast with those showing that NIH3T3 stable transfectants
overexpressing UbcH10 exhibited a malignant phenotype as
compared with parental NIH3T3 cells (Okamoto et al, 2003). This
discrepancy is, in our opinion, just apparent since we have to
consider that NIH 3T3 cells are preneoplastic cells, whereas PC Cl 3
cells are much more resistant to express the neoplastic phenotype,
since even the expression of several oncogenes (v-ras-Ki, v-ras-Ha,
etc.) are not able to lead these cells to the fully malignant
phenotype that is achieved only when there is a synergy of two
different oncogenes (Fusco et al, 1987). In conclusion, our data
propose the UbcH10 overexpression as a feature of the anaplastic
carcinoma histotype. The block of UbcH10 expression significantly
reduced the growth of thyroid carcinoma cell lines indicating an
involvement of UbcH10 in the increased proliferation of these
carcinoma cell lines. Therefore, these results open the perspective
of a therapy of the anaplastic thyroid carcinoma, one of the most
aggressive tumours in mankind, based on the suppression of the
UbcH10 synthesis and/or function.
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